|Bid||2.0500 x 900|
|Ask||2.1800 x 1000|
|Day's Range||2.0000 - 2.2499|
|52 Week Range||0.6110 - 4.4000|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CNSP
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms of cancer that are more deadly. Glioblastoma (GBM) is a highly aggressive ...
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)Topline result from preplanned interim futility analysis ...
HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM anywhere ...